AstraZeneca raises sales outlook as rival drugs are hit by delays
img, .hide-comment-buttons #singleCommentHeader .formContainer >.title, .hide-comment-buttons #loginButtonContainer display: none; /* Expandable MPU fix */ #side .x300 overflow: visible!important; /* Collapsing Skyscraper fix */ .ad div.skyscraper height:auto!important;padding:0px!important; .ad div#mpu.skyscraper height:600px!important; AstraZeneca raises sales outlook as rival drugs are hit by delays - Business News - Business - The Independent Tuesday 09 December 2014
Apps
eBooks
i Jobs
Dating
Shop
News UK Home News
UK Politics
Scottish independence
Crime
Weird News
World Europe
Americas
Middle East
Asia
Africa
Australasia
World Politics
World History
Novaya Gazeta (English)
WW1 Moments
Business Business News
Business Comment
Business Analysis & Features
Sharewatch
SME
Market News
Market Epic
Market Heatmaps
Market Screener
Business Directory
ES Business Connections
Create a business profile
People
Science
Environment Climate Change
Green Living
Nature
Media Opinion
TV & Radio
Press
Online
Advertising
Technology
Education News
Schools
Further
Higher
Primary Tables 2011
Secondary Tables 2012
Training & Courses
MBA & Executive
Images
Obituaries
Diary
Corrections
Newsletter
Appeals
Video
People
Voices
Sport
Tech
Life
Property
Arts + Ents
Travel
Money
IndyBest
Student
Offers
Cameron & Climate Change Breastfeeding Homeless Veterans Campaign - Donate George Osborne Greece Michael Gove News >Business >Business News AstraZeneca raises sales outlook as rival drugs are hit by delays Sales in the third quarter jumped 5% to $6.5 billion
Lucy Tobin Lucy Tobin Senior News Feature Writer at the Evening Standard, with business focus. Author of Ausperity, Entrepreneur + Guide to Uni Life.
More articles from this journalist Follow Lucy Tobin Thursday 06 November 2014
Print Your friend's email address Your email address Note: We do not store your email address(es) but your IP address will be logged to prevent abuse of this feature. Please read our Legal Terms & Policies A A A Email The single life suits drugs giant AstraZeneca.
The British pharma company posted its second sales upgrade in four months after rejecting Pfizer�s �70 billion takeover attempt this spring.
The firm was boosted by delays hitting the production of generic alternatives to its blockbuster ulcer and heartburn treatment, Nexium, in the crucial US market.
That helped sales in the third quarter rise 5 per cent to $6.5 billion (�4.06 billion), a third-consecutive quarter of revenue growth. Other top-sellers were heart drug Brilinta, which had a 78 per cent surge in sales, and its diabetes portfolio.
AstraZeneca now expects 2014�s revenues - when stripping out the effects of currency movements - to be higher by "low single digits" than last year.
Business news in pictures
That�s an upgrade from an earlier forecast of no growth, and comes after an original prediction that sales would fall by low-to-mid single digits was boosted in July by an announcement that annual sales would be flat.
But net profit fell to $254 million in the third quarter, from $1.25 billion a year earlier, as AstraZeneca poured nearly double the amount of money into research and development as it did in the same time in 2013.
Video: The latest business news At the start of this year, the FTSE 100 drugmaker was languishing in intensive care as its biggest medicines fell off patent and a string of cancer drug hopes failed at trials, triggering a share-price plunge.
Then, in May, Viagra-maker Pfizer began its prolonged and ultimately unsuccessful takeover attempt.
In fighting off that bid, AstraZeneca chief executive Pascal Soriot promised a 75 per cent increase in revenues to $45 billion by 2023 - but there�s a long way to go: City analysts forecast this year�s figure will hit just $25.9 billion.
Under UK takeover rules, Pfizer can mount a fresh bid for AstraZeneca from the end of this month.
Today Soriot cheered his "rapid transformation" of the drugmaker, but its shares fell 124p to 4494.75p.
Should you loved this short article and you want to receive more information concerning viagra price please visit our own site.
